Shyam Joshi, MD, reviews fundamental updates in the management of chronic spontaneous urticaria.

Shyam Joshi, MD, examines the evolving role of BTK inhibition, particularly remibrutinib, in the treatment algorithm for chronic spontaneous urticaria.

Shyam Joshi, MD, discusses the rapid onset of action and favorable safety profile of remibrutinib, distinguishing it among therapies for CSU.

Shyam Joshi, MD, highlights the practical and patient-centered advantages of oral BTK inhibitors in the management of chronic spontaneous urticaria.

Shyam Joshi, MD, reviews clinical and mechanistic data on remibrutinib in chronic spontaneous urticaria, as presented at ACAAI 2025 and EADV 2025.

Shyam Joshi explores the expected incorporation of new therapies within updated CSU guidelines and their anticipated impact on clinical management strategies.